Vertex Pharmaceuticals Incorporated
HealthcareNASDAQ:VRTX · NASDAQ Global Select
-$0.12 today
Vol 0.92M · Avg 1.26M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $5.5B |
| Short-term Investments | $1.8B |
| Receivables | $2.0B |
| Inventory | $1.8B |
| Other Current | $720.8M |
| Total Current Assets | $11.7B |
| PP&E (Net) | $1.6B |
| Goodwill | $1.1B |
| Intangible Assets | $418.5M |
| Long-term Investments | $5.7B |
| Tax Assets | $2.9B |
| Other Non-current | $2.9B |
| Total Non-current Assets | $14.8B |
| Total Assets | $26.5B |
Analysis
Selected assets total $26.5B for Latest. The largest visible component is Long-term Investments at $5.7B, about 21.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.1B +11.3% | $4.6B -55.9% | $10.4B -1.3% | $10.5B +54.6% | $6.8B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $1.5B -1.5% | $1.5B +82.1% | $849.2M +209.4% | $274.5M -62.4% | $729.9M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $2.1B +27.6% | $1.6B +2.9% | $1.6B +8.4% | $1.4B +26.9% | $1.1B | $533.8M | $399.4M | -$1.7B |
| Inventory | $1.7B +39.9% | $1.2B +63.2% | $738.8M +60.4% | $460.6M +30.4% | $353.1M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $748.6M +262.5% | $206.5M +139.8% | $86.1M -29.4% | $121.9M +17.6% | $103.7M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $11.2B +16.7% | $9.6B -32.2% | $14.1B +6.9% | $13.2B +38.4% | $9.6B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $3.1B +19.3% | $2.6B +77.9% | $1.5B -0.2% | $1.5B +2.2% | $1.4B | $1.2B | $1.5B | $687.8M |
| Goodwill | $1.1B +0.0% | $1.1B +0.0% | $1.1B +0.0% | $1.1B +8.6% | $1.0B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $424.2M -48.6% | $825.9M -1.7% | $839.9M +39.1% | $603.6M +50.9% | $400.0M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $5.8B +13.7% | $5.1B +104.5% | $2.5B +2126.2% | $112.2M | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $3.4B +45.8% | $2.3B +28.6% | $1.8B +45.3% | $1.2B +33.4% | $934.5M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $1.1B +14.3% | $999.3M +11.6% | $895.3M +118.6% | $409.6M +269.7% | $110.8M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $14.9B +15.5% | $12.9B +50.7% | $8.6B +74.7% | $4.9B +27.0% | $3.9B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $26.1B +16.0% | $22.5B -0.9% | $22.7B +25.2% | $18.2B +35.1% | $13.4B | $13.3B | $11.9B | $10.6B |
| Account Payables | $461.7M +11.8% | $413.0M +13.2% | $364.9M +20.1% | $303.9M +55.8% | $195.0M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $82.8M -10.3% | $92.3M | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $161.1M +61.9% | $99.5M -19.3% | $123.3M -41.6% | $211.3M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $171.8M -16.9% | $206.8M +21.4% | $170.3M +6.7% | $159.6M -7.0% | $171.7M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $2.7B +9.9% | $2.5B +4831.8% | $50.7M -18.9% | $62.5M +278.8% | $16.5M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $3.9B +8.3% | $3.6B +0.5% | $3.5B +29.4% | $2.7B +28.0% | $2.1B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $1.8B | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $1.3B | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | -$1.5B -265.2% | $901.8M +2.7% | $877.7M +28.0% | $685.8M +126.1% | $303.3M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $3.6B +41.3% | $2.6B +59.7% | $1.6B +7.1% | $1.5B +25.7% | $1.2B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $7.5B +22.1% | $6.1B +18.9% | $5.1B +21.5% | $4.2B +27.2% | $3.3B | $14.7B | $3.7B | $9.6B |
| Common Stock | $2.5M -3.8% | $2.6M +0.0% | $2.6M +0.0% | $2.6M +4.0% | $2.5M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $13.6B +41.2% | $9.6B -5.3% | $10.1B +55.5% | $6.5B +103.8% | $3.2B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$15.9M -112.4% | $127.8M +993.7% | -$14.3M -1887.5% | $800.0K -95.0% | $15.9M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $18.7B +13.7% | $16.4B -6.7% | $17.6B +26.4% | $13.9B +37.7% | $10.1B | $9.1B | $7.7B | $3.3B |
| Total Debt | $3.9B +121.9% | $1.7B +116.4% | $808.4M -10.1% | $899.7M -7.0% | $967.4M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$1.2B +57.3% | -$2.8B +70.5% | -$9.6B +0.5% | -$9.6B -64.8% | -$5.8B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$130.09B
Stryker Corporation
NYSE:SYK
$119.69B
Bristol-Myers Squibb Company
NYSE:BMY
$116.66B
Sanofi
NASDAQ:SNY
$106.39B
GSK plc
NYSE:GSK
$106.31B
Medtronic plc
NYSE:MDT
$102.97B
McKesson Corporation
NYSE:MCK
$94.25B
HCA Healthcare, Inc.
NYSE:HCA
$85.89B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.06B
argenx SE
NASDAQ:ARGX
$55.29B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does VRTX have?
Vertex Pharmaceuticals Incorporated (VRTX) reported $5.09B in cash and equivalents in fiscal 2025.
How much debt does VRTX carry?
Vertex Pharmaceuticals Incorporated (VRTX) reported $3.88B of total debt, with net debt of -$1,205,300,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.